BMC Infectious Diseases · 2014 · 33 citations · 11 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceAntimicrobial Resistance EpidemiologyBacteriologyAntibacterial ResistanceAntibiotic ResistanceAntibiotic Resistance MechanismsMultidrug ResistanceResistance EpidemiologyResistance SurveillanceAntibiotic Resistance In Bloodstream IsolatesAntimicrobial Prescribing PatternsAntimicrobial Resistance IndicatorsAntimicrobial Resistance PatternsAntimicrobial Resistance Trend AnalysisDrug Resistance Pattern AnalysisDrug Resistance PatternsResistance Incidence Trends
BACKGROUND: Increasing multidrug resistance in gram-negative bacilli (GNB) infections poses a serious threat to public health. Few studies have analyzed co-resistance rates, defined as an antimicrobial susceptibility profile in a subset already resistant to one specific antibiotic. The epidemiologic and clinical utility of determining co-resistance rates are analyzed and discussed. METHODS: A 10-year retrospective study from 2002-2011 of bloodstream infections with GNB were analyzed from three hospitals in Greater Vancouver, BC, Canada. Descriptive statistics were calculated for antimicrobial resistance and co-resistance. Statistical analysis further described temporal trends of antimicrobial resistance, correlations of resistance between combinations of antimicrobials, and temporal trends in co-resistance patterns. RESULTS: The total number of unique blood stream isolates of GNB was 3280. Increasing resistance to individual antimicrobials was observed for E. coli, K. pneumoniae, K. oxytoca, E. cloacae, and P. aeruginosa. Ciprofloxacin resistance in E. coli peaked in 2006 at 40% and subsequently stabilized at 29% in 2011, corresponding to decreasing ciprofloxacin usage after 2007, as assessed by defined daily dose utilization data. High co-resistance rates were observed for ceftriaxone-resistant E. coli with ciprofloxacin (73%), ceftriaxone-resistant K. pneumoniae with trimethoprim-sulfamethoxazole (83%), ciprofloxacin-resistant E. cloacae with ticarcillin-clavulanate (91%), and piperacillin-tazobactam-resistant P. aeruginosa with ceftazidime (83%). CONCLUSIONS: Increasing antimicrobial resistance was demonstrated over the study period, which may partially be associated with antimicrobial consumption. The study of co-resistance rates in multidrug resistant GNB provides insight into the epidemiology of resistance acquisition, and may be used as a clinical tool to aid prescribing empiric antimicrobial therapy.
11
Shawn R. Lockhart, Murray A. Abramson, Susan E. Beekmann et al. · Journal of Clinical Microbiology · 2007 · 398 citations · Full text
Kennard Tan, Brandon Ellis, Renee T. Lee et al. · Journal of Clinical Microbiology · 2012 · 320 citations · Full text
Jean‐Louis Trouillet, Albert Vuagnat, Alain Combes et al. · Clinical Infectious Diseases · 2002 · 181 citations
Elisabeth Paramythiotou, Jean‐Christophe Lucet, Jean‐François Timsit et al. · Clinical Infectious Diseases · 2004 · 176 citations · Full text